Zoledronic acid: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Kiran Singh (talk | contribs)
nocaptcha, Administrators
24,170 edits
No edit summary
Kiran Singh (talk | contribs)
nocaptcha, Administrators
24,170 edits
No edit summary
Line 7: Line 7:
|indication=[[hypercalcemia]] of malignancy,  [[multiple myeloma,]],  bone metastases of solid tumors,  [[osteoporosis]],
|indication=[[hypercalcemia]] of malignancy,  [[multiple myeloma,]],  bone metastases of solid tumors,  [[osteoporosis]],
[[paget's disease]],  postmenopausal [[osteoporosis]]
[[paget's disease]],  postmenopausal [[osteoporosis]]
|adverseReactions=[[nausea]],   [[fatigue,]],  [[anemia]],  [[bone pain]],  [[constipation]],  [[fever]],  [[vomiting]],  [[dyspnea]]
|adverseReactions=[[nausea]], fatigue, [[anemia]],  [[bone pain]],  [[constipation]],  [[fever]],  [[vomiting]],  [[dyspnea]]
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
Line 16: Line 16:


<!--FDA-Labeled Indications and Dosage (Adult)-->
<!--FDA-Labeled Indications and Dosage (Adult)-->
|fdaLIADAdult======Condition1=====
|fdaLIADAdult===Indications==


* Dosing Information
'''Hypercalcemia of Malignancy'''


:* Dosage
Zoledronic acid Injection is indicated for the treatment of  [[hypercalcemia]] of malignancy defined as an albumin-corrected calcium (cCa) of greater than or equal to 12 mg/dL [3.0 mmol/L] using the formula: cCa in mg/dL =Ca in mg/dL + 0.8 ( 4.0 g/dL – patient albumin [g/dL]).


=====Condition2=====
'''Multiple Myeloma and Bone Metastases of Solid Tumors'''
Zoledronic acid Injection is indicated for the treatment of patients with [[multiple myeloma]] and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.


* Dosing Information
'''Important Limitation of Use'''


:* Dosage
The safety and efficacy of Zoledronic acid Injection in the treatment of  [[hypercalcemia]] associated with [[hyperparathyroidism]] or with other nontumor-related conditions have not been established.
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
|offLabelAdultGuideSupport======Condition1=====


Revision as of 16:32, 16 January 2015

Zoledronic acid
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Zoledronic acid is a bisphosphonate that is FDA approved for the treatment of hypercalcemia of malignancy, multiple myeloma,, bone metastases of solid tumors, osteoporosis, paget's disease, postmenopausal osteoporosis. Common adverse reactions include nausea, fatigue, anemia, bone pain, constipation, fever, vomiting, dyspnea.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

Hypercalcemia of Malignancy

Zoledronic acid Injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cCa) of greater than or equal to 12 mg/dL [3.0 mmol/L] using the formula: cCa in mg/dL =Ca in mg/dL + 0.8 ( 4.0 g/dL – patient albumin [g/dL]).

Multiple Myeloma and Bone Metastases of Solid Tumors

Zoledronic acid Injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.

Important Limitation of Use

The safety and efficacy of Zoledronic acid Injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other nontumor-related conditions have not been established.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Zoledronic acid in adult patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Zoledronic acid in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Zoledronic acid in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Zoledronic acid in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Zoledronic acid in pediatric patients.

Contraindications

  • Condition1

Warnings

  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Zoledronic acid in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Zoledronic acid in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Zoledronic acid in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Zoledronic acid during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Zoledronic acid with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Zoledronic acid with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Zoledronic acid with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Zoledronic acid with respect to specific gender populations.

Race

There is no FDA guidance on the use of Zoledronic acid with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Zoledronic acid in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Zoledronic acid in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Zoledronic acid in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Zoledronic acid in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Zoledronic acid in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Zoledronic acid in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Zoledronic acid in the drug label.

Pharmacology

There is limited information regarding Zoledronic acid Pharmacology in the drug label.

Mechanism of Action

Structure

File:Zoledronic acid01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Zoledronic acid in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Zoledronic acid in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Zoledronic acid in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Zoledronic acid in the drug label.

How Supplied

Storage

There is limited information regarding Zoledronic acid Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Zoledronic acid |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Zoledronic acid |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Zoledronic acid in the drug label.

Precautions with Alcohol

  • Alcohol-Zoledronic acid interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Empty citation (help)
  2. ↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject: 

 |Page Name=Zoledronic acid
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject: 

 |Label Page=Zoledronic acid
 |Label Name=Zoledronic acid11.png

}}

{{#subobject: 

 |Label Page=Zoledronic acid
 |Label Name=Zoledronic acid11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Zoledronic_acid&oldid=1055609"